

# Giovanni Cazzaniga

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8596198/publications.pdf>

Version: 2024-02-01

336  
papers

18,196  
citations

18887

64  
h-index

17373

126  
g-index

338  
all docs

338  
docs citations

338  
times ranked

16586  
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement. <i>Haematologica</i> , 2023, 108, 717-731.	1.7	6
2	Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium. <i>Blood</i> , 2022, 139, 1785-1793.	0.6	28
3	Clonal dynamics in pediatric B-cell precursor acute lymphoblastic leukemia with very early relapse. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29361.	0.8	9
4	Identical <i>EP300</i> variant leading to Rubinstein-Taybi syndrome with different clinical and immunologic phenotype. <i>American Journal of Medical Genetics, Part A</i> , 2022, 188, 2129-2134.	0.7	2
5	Recurrent Germline Variant in <i>RAD21</i> Predisposes Children to Lymphoblastic Leukemia or Lymphoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5174.	1.8	2
6	Minimal Residual Disease Analysis by Monitoring Immunoglobulin and T-Cell Receptor Gene Rearrangements by Quantitative PCR and Droplet Digital PCR. <i>Methods in Molecular Biology</i> , 2022, , 79-89.	0.4	3
7	<i>FLT3-ITD</i> in Children with Early T-cell Precursor (ETP) Acute Lymphoblastic Leukemia: Incidence and Potential Target for Monitoring Minimal Residual Disease (MRD). <i>Cancers</i> , 2022, 14, 2475.	1.7	3
8	Potential role of <i>STAG1</i> mutations in genetic predisposition to childhood hematological malignancies. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	2
9	The immune checkpoint <i>ICOSLG</i> is a relapse-predicting biomarker and therapeutic target in infant <i>t(4;11)</i> acute lymphoblastic leukemia. <i>IScience</i> , 2022, , 104613.	1.9	6
10	<i>HDAC7</i> is a major contributor in the pathogenesis of infant <i>t(4;11)</i> proB acute lymphoblastic leukemia. <i>Leukemia</i> , 2021, 35, 2086-2091.	3.3	8
11	<i>SSBP2-CSF1R</i> is a recurrent fusion in B-lineage acute lymphoblastic leukemia with diverse genetic presentation and variable outcome. <i>Blood</i> , 2021, 137, 1835-1838.	0.6	6
12	Absent B cells, agammaglobulinemia, and hypertrophic cardiomyopathy in folliculin-interacting protein 1 deficiency. <i>Blood</i> , 2021, 137, 493-499.	0.6	26
13	Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with <i>ABL</i> -class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study. <i>Lancet Haematology</i> , the, 2021, 8, e55-e66.	2.2	32
14	Droplet Digital PCR Improves IG-/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia. <i>HemaSphere</i> , 2021, 5, e543.	1.2	20
15	Potential and pitfalls of whole transcriptome-based immunogenetic marker identification in acute lymphoblastic leukemia; a EuroMRD and EuroClonality-NGS Working Group study. <i>Leukemia</i> , 2021, 35, 924-928.	3.3	3
16	Clinical Implications of Minimal Residual Disease Detection in Infants With <i>KMT2A</i> -Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol. <i>Journal of Clinical Oncology</i> , 2021, 39, 652-662.	0.8	41
17	Clinical characteristics and outcomes of B-ALL with <i>ZNF384</i> rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group. <i>Leukemia</i> , 2021, 35, 3272-3277.	3.3	40
18	The Bone Marrow Niche in B-Cell Acute Lymphoblastic Leukemia: The Role of Microenvironment from Pre-Leukemia to Overt Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4426.	1.8	31

#	ARTICLE	IF	CITATIONS
19	Case Report: Hypomorphic Function and Somatic Reversion in DOCK8 Deficiency in One Patient With Two Novel Variants and Sclerosing Cholangitis. <i>Frontiers in Immunology</i> , 2021, 12, 673487.	2.2	5
20	Recurrent genetic fusions redefine <i>MLL</i> germ line acute lymphoblastic leukemia in infants. <i>Blood</i> , 2021, 137, 1980-1984.	0.6	12
21	Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts. , 2021, 9, e001514.		10
22	Chemotherapy induces canalization of cell state in childhood B-cell precursor acute lymphoblastic leukemia. <i>Nature Cancer</i> , 2021, 2, 835-852.	5.7	25
23	Integrative methylome-transcriptome analysis unravels cancer cell vulnerabilities in infant <i>MLL</i> -rearranged B cell acute lymphoblastic leukemia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	14
24	Favorable outcome of <i>NUTM1</i> -rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study. <i>Leukemia</i> , 2021, 35, 2978-2982.	3.3	40
25	Genetic and Epigenetic Characterization of a Discordant <i>KMT2A/AFF1</i> -Rearranged Infant Monozygotic Twin Pair. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9740.	1.8	1
26	Utilizing the prognostic impact of minimal residual disease in treatment decisions for pediatric acute lymphoblastic leukemia. <i>Expert Review of Hematology</i> , 2021, 14, 795-807.	1.0	4
27	PCR Technology to Identify Minimal Residual Disease. <i>Methods in Molecular Biology</i> , 2021, 2185, 77-94.	0.4	8
28	Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders. <i>Blood Advances</i> , 2021, 5, 3188-3198.	2.5	2
29	Potential Role of <i>STAG1</i> Mutations in Genetic Predisposition to Childhood Hemato-Oncological Diseases. <i>Blood</i> , 2021, 138, 1155-1155.	0.6	0
30	Recurrent Germline Variant in the Cohesin Complex Gene <i>RAD21</i> Predisposes Children to Lymphoblastic Leukemia and Lymphoma. <i>Blood</i> , 2021, 138, 3358-3358.	0.6	0
31	Implication of <i>ICOSLG</i> on Relapse in Infant T(4;11) Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 3481-3481.	0.6	0
32	Targeted Next Generation Sequencing Reveals a Third Breakpoint Cluster Region and New Partner Genes in the <i>KMT2A</i> Recombinome. <i>Blood</i> , 2021, 138, 3327-3327.	0.6	0
33	Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with Acute Lymphoblastic Leukemia Relapsed Post-HSCT. <i>Blood</i> , 2021, 138, 472-472.	0.6	2
34	Targeting <i>JAK2</i> Gene Rearrangements with a Novel Kinase Inhibitor in a Preclinical Model of Pediatric Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 1180-1180.	0.6	0
35	Efficacy of imatinib and chemotherapy in a pediatric patient with Philadelphia-like acute lymphoblastic leukemia with <i>Ebf1-Pdgfrb</i> fusion transcript. <i>Leukemia and Lymphoma</i> , 2020, 61, 469-472.	0.6	12
36	Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols. <i>Haematologica</i> , 2020, 105, 1887-1894.	1.7	33

#	ARTICLE	IF	CITATIONS
37	Next-generation sequencing of PTEN mutations for monitoring minimal residual disease in T-cell acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28025.	0.8	3
38	Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial. <i>Leukemia</i> , 2020, 34, 1694-1700.	3.3	24
39	More than an "atypical" phenotype: dual molecular diagnosis of autoimmune lymphoproliferative syndrome and Becker muscular dystrophy. <i>British Journal of Haematology</i> , 2020, 191, 291-294.	1.2	4
40	Two siblings presenting with novel ADA2 variants, lymphoproliferation, persistence of large granular lymphocytes, and T-cell perturbations. <i>Clinical Immunology</i> , 2020, 218, 108525.	1.4	15
41	High <i>EVI1</i> Expression due to <i>NRIP1/EVI1</i> Fusion in Therapy-related Acute Myeloid Leukemia: Description of the First Pediatric Case. <i>HemaSphere</i> , 2020, 4, e471.	1.2	3
42	Inhibition of inflammatory signaling in Pax5 mutant cells mitigates B-cell leukemogenesis. <i>Scientific Reports</i> , 2020, 10, 19189.	1.6	15
43	Pro-inflammatory cytokines favor the emergence of ETV6-RUNX1-positive pre-leukemic cells in a model of mesenchymal niche. <i>British Journal of Haematology</i> , 2020, 190, 262-273.	1.2	25
44	Implementation of RNA sequencing and array CGH in the diagnostic workflow of the AIEOP-BFM ALL 2017 trial on acute lymphoblastic leukemia. <i>Annals of Hematology</i> , 2020, 99, 809-818.	0.8	23
45	Dysregulation of NIPBL leads to impaired RUNX1 expression and haematopoietic defects. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 6272-6282.	1.6	8
46	Prenatal Origin of Pediatric Leukemia: Lessons From Hematopoietic Development. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 618164.	1.8	14
47	Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities. <i>Journal of Clinical Investigation</i> , 2020, 130, 6021-6033.	3.9	102
48	Incidence and Therapeutic Implications of Germline <i>TP53</i> Mutations in Hypodiploid Childhood Acute Lymphoblastic Leukemia: A Retrospective Analysis of the Italian Cohort. <i>Blood</i> , 2020, 136, 43-44.	0.6	0
49	Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study. <i>Leukemia</i> , 2019, 33, 2241-2253.	3.3	177
50	Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis. <i>Haematologica</i> , 2019, 104, 1176-1188.	1.7	76
51	<i>NIPBL</i> : a new player in myeloid cell differentiation. <i>Haematologica</i> , 2019, 104, 1332-1341.	1.7	22
52	Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS. <i>Leukemia</i> , 2019, 33, 2254-2265.	3.3	70
53	$\beta$ -Catenin-Dependent Signals Maintain BCR-ABL1+ B Cell Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2019, 35, 649-663.e10.	7.7	20
54	Deletions of Chromosome 7q Affect Nuclear Organization and HLXB9 Gene Expression in Hematological Disorders. <i>Cancers</i> , 2019, 11, 585.	1.7	21

#	ARTICLE	IF	CITATIONS
55	Human MLL/KMT2A gene exhibits a second breakpoint cluster region for recurrent MLL-USP2 fusions. <i>Leukemia</i> , 2019, 33, 2306-2340.	3.3	41
56	IKZF1 Deletions with COBL Breakpoints Are Not Driven by RAG-Mediated Recombination Events in Acute Lymphoblastic Leukemia. <i>Translational Oncology</i> , 2019, 12, 726-732.	1.7	7
57	Activin A contributes to the definition of a pro-oncogenic bone marrow microenvironment in t(12;21) preleukemia. <i>Experimental Hematology</i> , 2019, 73, 7-12.e4.	0.2	9
58	Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1. <i>Leukemia</i> , 2019, 33, 1910-1922.	3.3	54
59	First evidence of a paediatric patient with Cornelia de Lange syndrome with acute lymphoblastic leukaemia. <i>Journal of Clinical Pathology</i> , 2019, 72, 558-561.	1.0	10
60	More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. <i>Blood Advances</i> , 2019, 3, 3393-3405.	2.5	81
61	A Simple RNA Target Capture NGS Strategy for Fusion Genes Assessment in the Diagnostics of Pediatric B-Cell Acute Lymphoblastic Leukemia. <i>HemaSphere</i> , 2019, 3, e250.	1.2	13
62	Shwachman-Diamond syndrome with clonal interstitial deletion of the long arm of chromosome 20 in bone marrow: haematological features, prognosis and genomic instability. <i>British Journal of Haematology</i> , 2019, 184, 974-981.	1.2	24
63	Modeling Cornelia de Lange syndrome in vitro and in vivo reveals a role for cohesin complex in neuronal survival and differentiation. <i>Human Molecular Genetics</i> , 2019, 28, 64-73.	1.4	20
64	Acute Lymphoblastic Leukemia with Zinc-Finger Protein 384 (ZNF384)-Related Rearrangements: A Retrospective Analysis from the Ponte Di Legno Childhood ALL Working Group. <i>Blood</i> , 2019, 134, 652-652.	0.6	6
65	Donor-Derived CD19 CAR Cytokine Induced Killer (CIK) Cells Engineered with Sleeping Beauty Transposon for Relapsed B-Cell Acute Lymphoblastic Leukemia (B-ALL). <i>Blood</i> , 2019, 134, 200-200.	0.6	5
66	Euroclonality-NGS DNA Capture Panel for Integrated Analysis of IG/TR Rearrangements, Translocations, Copy Number and Sequence Variation in Lymphoproliferative Disorders. <i>Blood</i> , 2019, 134, 888-888.	0.6	4
67	Pre-Clinical Efficacy of the Novel Kinase Inhibitor Nintedanib on PAX5 Fusion Genes in Pediatric Ph-like B-Cell Precursor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 745-745.	0.6	0
68	Transient Switch to Myeloid Lineage in Acute Lymphoblastic Leukemia during Induction Therapy: The Role of CD371 Expression and Implication for Minimal Residual Disease Detection. <i>Blood</i> , 2019, 134, 377-377.	0.6	1
69	Poor Prognosis in Children with ABL-Class Fusion Positive B-Cell Acute Lymphoblastic Leukemia Treated According to AIEOP-BFM Protocols. <i>Blood</i> , 2019, 134, 1351-1351.	0.6	4
70	Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia. <i>Human Gene Therapy</i> , 2018, 29, 602-613.	1.4	35
71	Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2018, 180, 680-693.	1.2	44
72	AKR1C enzymes sustain therapy resistance in paediatric T-ALL. <i>British Journal of Cancer</i> , 2018, 118, 985-994.	2.9	31

#	ARTICLE	IF	CITATIONS
73	<scp>TNFRSF</scp>13C (<scp>BAFFR</scp>) positive blasts persist after early treatment and at relapse in childhood Bâ€cell precursor acute lymphoblastic leukaemia. British Journal of Haematology, 2018, 182, 434-436.	1.2	8
74	The MLL recombinome of acute leukemias in 2017. Leukemia, 2018, 32, 273-284.	3.3	527
75	Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies. Haematologica, 2018, 103, 107-115.	1.7	68
76	Engineered T cells towards TNFRSF13C (<scp>BAFFR</scp>): a novel strategy to efficiently target Bâ€cell acute lymphoblastic leukaemia. British Journal of Haematology, 2018, 182, 939-943.	1.2	19
77	DNA variants in <i>DHFR</i> gene and response to treatment in children with childhood B ALL: revisited in AIEOP-BFM protocol. Pharmacogenomics, 2018, 19, 105-112.	0.6	11
78	<i>IKZF1</i><sup>plus</sup> Defines a New Minimal Residual Diseaseâ€Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2018, 36, 1240-1249.	0.8	194
79	Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia. JNCI Cancer Spectrum, 2018, 2, pky069.	1.4	10
80	Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial. Lancet Haematology, the, 2018, 5, e641-e652.	2.2	78
81	Genetic risk factors for VIPN in childhood acute lymphoblastic leukemia patients identified using whole-exome sequencing. Pharmacogenomics, 2018, 19, 1181-1193.	0.6	27
82	The presence of mutated and deleted <scp>PTEN</scp> is associated with an increased risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with <scp>AIEOP</scp>â€<scp>BFM ALL</scp> protocols. British Journal of Haematology, 2018, 182, 705-711.	1.2	30
83	Rings and Bricks: Expression of Cohesin Components is Dynamic during Development and Adult Life. International Journal of Molecular Sciences, 2018, 19, 438.	1.8	4
84	Antileukemic Efficacy of BET Inhibitor in a Preclinical Mouse Model of MLL-AF4+ Infant ALL. Molecular Cancer Therapeutics, 2018, 17, 1705-1716.	1.9	18
85	The Methylome Landscape of Infant B-Cell Precursor Acute Lymphoblastic Leukemia. Experimental Hematology, 2018, 64, S85-S86.	0.2	0
86	A Novel Inducible Mouse Model of <i>MLLâ€ENL</i>-driven Mixedâ€lineage Acute Leukemia. HemaSphere, 2018, 2, e51.	1.2	14
87	MLL-USP2: An Underestimated New Entity of MLL-Rearranged Leukemia Identified By NGS Analysis. Blood, 2018, 132, 3920-3920.	0.6	2
88	Digital-Droplet PCR, an Accurate Method for IG/TR PCR-MRD Stratification in Childhood Acute Lymphoblastic Leukemia. Blood, 2018, 132, 1544-1544.	0.6	4
89	SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia. Oncotarget, 2018, 9, 22872-22885.	0.8	11
90	Bone Marrow Mesenchymal Stromal Cells and Inflammation Contribute to ETV6-RUNX1+ Preleukemic Cells Persistence and DNA Damaging. Blood, 2018, 132, 3918-3918.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Successful of Chemo-Free Treatment with Dasatinib and Blinatumomab in a Pediatric EBF1-PDGFR <sup>2</sup> Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 5213-5213.	0.6	3
92	Characterization of children with FLT3-ITD acute myeloid leukemia: a report from the AIEOP AML-2002 study group. <i>Leukemia</i> , 2017, 31, 18-25.	3.3	29
93	Phosphoproteomic analysis reveals hyperactivation of mTOR/STAT3 and LCK/Calcineurin axes in pediatric early T-cell precursor ALL. <i>Leukemia</i> , 2017, 31, 1007-1011.	3.3	27
94	Metabolic gatekeeper function of B-lymphoid transcription factors. <i>Nature</i> , 2017, 542, 479-483.	13.7	175
95	High-Throughput Immunogenetics for Clinical and Research Applications in Immunohematology: Potential and Challenges. <i>Journal of Immunology</i> , 2017, 198, 3765-3774.	0.4	61
96	Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E4030-E4039.	3.3	62
97	Possible role of pandemic AH1N1 swine flu virus in a childhood leukemia cluster. <i>Leukemia</i> , 2017, 31, 1819-1821.	3.3	23
98	The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL. <i>Leukemia</i> , 2017, 31, 2365-2375.	3.3	33
99	Acute myeloid leukemia in Baraitser's "Winter cerebrofrontofacial syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2017, 173, 546-549.	0.7	11
100	An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 953-963.	1.5	17
101	Impairment of Retinoic Acid Signaling in Cornelia de Lange Syndrome Fibroblasts. <i>Birth Defects Research</i> , 2017, 109, 1268-1276.	0.8	5
102	Intragenic amplification of PAX5: a novel subgroup in B-cell precursor acute lymphoblastic leukemia?. <i>Blood Advances</i> , 2017, 1, 1473-1477.	2.5	25
103	CA180-372: An International Collaborative Phase 2 Trial of Dasatinib and Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+) <a href="#">Tj ETQq1 10067843143gBT /O</a>		
104	High expression of miR-125b-2 and SNORD116 noncoding RNA clusters characterize ERG-related B cell precursor acute lymphoblastic leukemia. <i>Oncotarget</i> , 2017, 8, 42398-42413.	0.8	19
105	A Treatment Protocol with Imatinib and Intensive Chemotherapy for Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia Patients: A Single-Arm, Intergroup Study (EsPhALL 2010-2014). <i>Blood</i> , 2017, 130, 97-97.	0.6	1
106	Hodgkin lymphoma in a patient with mosaic trisomy 18: First clinical observation. <i>American Journal of Medical Genetics, Part A</i> , 2016, 170, 777-780.	0.7	5
107	CyclinD1 Down-Regulation and Increased Apoptosis Are Common Features of Cohesinopathies. <i>Journal of Cellular Physiology</i> , 2016, 231, 613-622.	2.0	16
108	A Case of T-cell Acute Lymphoblastic Leukemia Relapsed As Myeloid Acute Leukemia. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1660-1663.	0.8	10

#	ARTICLE	IF	CITATIONS
109	Clinical and molecular genetic characterization of wild-type MLL infant acute lymphoblastic leukemia identifies few recurrent abnormalities. <i>Haematologica</i> , 2016, 101, e95-e99.	1.7	17
110	Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. <i>Blood</i> , 2016, 127, 2101-2112.	0.6	208
111	Role of CXCR4-mediated bone marrow colonization in CNS infiltration by T cell acute lymphoblastic leukemia. <i>Journal of Leukocyte Biology</i> , 2016, 99, 1077-1087.	1.5	41
112	Characterization of leukemias with ETV6-ABL1 fusion. <i>Haematologica</i> , 2016, 101, 1082-1093.	1.7	66
113	Developmental refractoriness of MLL-rearranged human acute B-cell leukemias. <i>Experimental Hematology</i> , 2016, 44, S40.	0.2	0
114	Development Refractoriness of MLL-Rearranged Human B Cell Acute Leukemias to Reprogramming into Pluripotency. <i>Stem Cell Reports</i> , 2016, 7, 602-618.	2.3	38
115	Williams syndrome and mature B-Leukemia: A random association?. <i>European Journal of Medical Genetics</i> , 2016, 59, 634-640.	0.7	9
116	Deciphering KRAS and NRAS mutated clone dynamics in MLL-AF4 paediatric leukaemia by ultra deep sequencing analysis. <i>Scientific Reports</i> , 2016, 6, 34449.	1.6	20
117	Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis. <i>Lancet Haematology</i> , the, 2016, 3, e80-e86.	2.2	95
118	PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. <i>Nature Medicine</i> , 2016, 22, 379-387.	15.2	94
119	Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study. <i>Leukemia</i> , 2016, 30, 32-38.	3.3	81
120	Sleeping Beauty Modified CAR+ Lymphocytes Engraft and Exhibit Anti-Tumor Activity in Patient-Derived Xenograft Models of Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 4022-4022.	0.6	1
121	<i>CRLF2</i> over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia. <i>Oncotarget</i> , 2016, 7, 59260-59272.	0.8	24
122	Acute Lymphoblastic Leukemia. , 2016, , 561-577.		0
123	The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy. <i>Blood</i> , 2016, 128, 3097-3097.	0.6	0
124	A Versatile DNA/RNA NGS Targeted Capture Strategy for Detection of Fusion Genes in Pediatric ALL. <i>Blood</i> , 2016, 128, 2913-2913.	0.6	0
125	Immunomodulatory Interventions Based on Minimal Residual Disease before and after Transplantation for Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 3480-3480.	0.6	0
126	Evaluation of Minimal Residual Disease As a Surrogate Endpoint for Event Free Survival in Childhood B-Lineage Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 759-759.	0.6	0



#	ARTICLE	IF	CITATIONS
127	Transcriptional Control of Glucose and Energy Supply Prevents Oncogenic Signaling and B Cell Transformation. <i>Blood</i> , 2016, 128, 437-437.	0.6	0
128	Fine tuning of surface CRLF2 expression and its associated signaling profile in childhood B-cell precursor acute lymphoblastic leukemia. <i>Haematologica</i> , 2015, 100, e229-e232.	1.7	29
129	Nodal monoclonal CD5-positive B-lymphocytosis and toxoplasma lymphadenitis: another variant in the spectrum of infectious lymphadenitis in patients with chronic leukemia/small lymphocytic lymphoma. <i>Expert Review of Hematology</i> , 2015, 8, 563-565.	1.0	0
130	Noonan syndrome-like disorder with loose anagen hair: A second case with neuroblastoma. <i>American Journal of Medical Genetics, Part A</i> , 2015, 167, 1902-1907.	0.7	14
131	<i>LCK</i> over-expression drives STAT5 oncogenic signaling in <i>PAX5</i> translocated BCP-ALL patients. <i>Oncotarget</i> , 2015, 6, 1569-1581.	0.8	17
132	GOOD OUTCOME FOR VERY HIGH RISK ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA CARRYING GENETIC ABNORMALITIES t(4;11)(q21;q23) or t(9;22)(q34;q11), IF PROMPTLY SUBMITTED TO ALLOGENEIC TRANSPLANTATION, AFTER OBTAINING A GOOD MOLECULAR REMISSION.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2015, 7, e2015041.	0.5	5
133	Clinical features and outcome of SIL/TAL1-positive T-cell acute lymphoblastic leukemia in children and adolescents: a 10-year experience of the AIEOP group. <i>Haematologica</i> , 2015, 100, e10-e13.	1.7	35
134	Refinement of IKZF1 status in pediatric Philadelphia-positive acute lymphoblastic leukemia. <i>Leukemia</i> , 2015, 29, 2107-2110.	3.3	18
135	KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia. <i>Leukemia</i> , 2015, 29, 1656-1667.	3.3	90
136	Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement. <i>Leukemia</i> , 2015, 29, 38-50.	3.3	48
137	Risk factors for relapse in childhood acute lymphoblastic leukemia: prediction and prevention. <i>Expert Review of Hematology</i> , 2015, 8, 57-70.	1.0	30
138	Three novel fusion transcripts of the paired box 5 gene in B-cell precursor acute lymphoblastic leukemia. <i>Haematologica</i> , 2015, 100, e14-e17.	1.7	11
139	Library Preparation Is the Major Factor Affecting Differences in Results of Immunoglobulin Gene Rearrangements Detection on Two Major Next-Generation Sequencing Platforms. <i>Blood</i> , 2015, 126, 1411-1411.	0.6	1
140	Role of the Histone Deacetylase Inhibitor Givinostat (ITF2357) in Treatment of CRLF2 Rearranged Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 2534-2534.	0.6	1
141	International Laboratory Comparison of Methodologies for Determining Minimal Residual Disease (MRD) in Childhood Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). <i>Blood</i> , 2015, 126, 2612-2612.	0.6	2
142	Clonal Evolution and Lack of BCR-ABL1 Mutations in Pediatric Ph+ ALL Patients Resistant/Refractory to Imatinib Treatment. <i>Blood</i> , 2015, 126, 2622-2622.	0.6	3
143	Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical model. <i>Oncotarget</i> , 2015, 6, 1382-1395.	0.8	11
144	Rapid Identification of BCR/ABL1-like Acute Lymphoblastic Leukemia (ALL) Cases By Quantitative Real Time-PCR (Q-RT-PCR). Generation and Validation of a Predictive Statistical Model. <i>Blood</i> , 2015, 126, 1410-1410.	0.6	0

#	ARTICLE	IF	CITATIONS
145	Genetics Directing Therapy in Acute Lymphocytic Leukemia: Identifying Risk, Defining Targets. <i>Blood</i> , 2015, 126, SCI-35-SCI-35.	0.6	0
146	Clinical and Biological Characterization of Children with FLT3ITD Mutated Acute Myeloid Leukemia (AML): A Report from the AIEOP AML-2002 Study Group. <i>Blood</i> , 2015, 126, 3845-3845.	0.6	0
147	Mass Cytometry Analysis Dissects CRLF2-Driven Signaling Pathways in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL). <i>Blood</i> , 2015, 126, 906-906.	0.6	0
148	Characterization of Leukemias with ETV6-ABL1 Fusion. <i>Blood</i> , 2015, 126, 84-84.	0.6	1
149	B-Lymphoid Transcription Factors Restrict Glycolytic Energy Supply for Oncogenic Signaling. <i>Blood</i> , 2015, 126, 1255-1255.	0.6	0
150	Isolation and Characterization of Mesenchymal Stromal Cells Derived from Paediatric Patients with B Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 4771-4771.	0.6	0
151	The role of PAX5 and C/EBP $\beta$ in atypical non-Langerhans cell histiocytic tumor post acute lymphoblastic leukemia. <i>Leukemia</i> , 2014, 28, 1377-1379.	3.3	6
152	Frequent and sex-biased deletion of SLX4IP by illegitimate V(D)J-mediated recombination in childhood acute lymphoblastic leukemia. <i>Human Molecular Genetics</i> , 2014, 23, 590-601.	1.4	13
153	Occult monoclonal B-cell disorder of hyoid bone. <i>Hematological Oncology</i> , 2014, 32, 107-109.	0.8	1
154	Postinduction Minimal Residual Disease Monitoring by Polymerase Chain Reaction in Children With Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2014, 32, 3553-3558.	0.8	28
155	Cytoskeletal Regulatory Gene Expression and Migratory Properties of B-cell Progenitors Are Affected by the ETV6-RUNX1 Rearrangement. <i>Molecular Cancer Research</i> , 2014, 12, 1796-1806.	1.5	10
156	Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?. <i>British Journal of Haematology</i> , 2014, 164, 396-408.	1.2	76
157	An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. <i>Leukemia</i> , 2014, 28, 1015-1021.	3.3	175
158	RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2014, 46, 116-125.	9.4	313
159	Novel activating mutations lacking cysteine in type I cytokine receptors in acute lymphoblastic leukemia. <i>Blood</i> , 2014, 124, 106-110.	0.6	50
160	IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. <i>Blood</i> , 2014, 123, 1691-1698.	0.6	129
161	Genetic profile of T-cell acute lymphoblastic leukemias with MYC translocations. <i>Blood</i> , 2014, 124, 3577-3582.	0.6	49
162	CRLF2 over-Expression Is a Poor Prognostic Marker in Children with High Risk T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 1071-1071.	0.6	2

#	ARTICLE	IF	CITATIONS
163	FLT3-ITD As a Target for Minimal Residual Disease Monitoring in Early T-Cell Precursor (ETP) Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 1073-1073.	0.6	1
164	The Strong Prognostic Effect of Concurrent Deletions of IKZF1 and PAX5, CDKN2A, CDKN2B or PAR1 in the Absence of ERG Deletions (IKZF1plus) in Pediatric Acute Lymphoblastic Leukemia Strongly Depends on Minimal Residual Disease Burden after Induction Treatment. <i>Blood</i> , 2014, 124, 131-131.	0.6	4
165	Prognostic Value of Rare IKZF1 deletions in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia: An International Collaborative Study. <i>Blood</i> , 2014, 124, 368-368.	0.6	3
166	Outcome of Early T-Cell Precursor Acute Lymphoblastic Leukemia in AIEOP Patients Treated with the AIEOP-BFM ALL 2000 Study. <i>Blood</i> , 2014, 124, 3780-3780.	0.6	1
167	Low $\beta$ -tubulin expression within the MRD-HR stratum defines a new subgroup of childhood T-ALL with very poor outcome. <i>Oncotarget</i> , 2014, 5, 5234-5245.	0.8	20
168	PTEN Is Essential for Normal Cytokine Signaling and Oncogenic Transformation of Pre-B Cells. <i>Blood</i> , 2014, 124, 262-262.	0.6	0
169	Refinement of IKZF1 Genomic Status in Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 3785-3785.	0.6	0
170	Comparison of MRD Monitoring By IG/TR Rearrangement and BCR/ABL1 Transcript in Ph+ Pediatric Acute Lymphoblastic Leukemia Patients Treated with Imatinib in the Esphall Study. <i>Blood</i> , 2014, 124, 3782-3782.	0.6	0
171	Loss of PTEN in Pediatric T-Cell Acute Lymphoblastic Leukemia Patients: Proteomic and Molecular Characterization. <i>Blood</i> , 2014, 124, 2408-2408.	0.6	4
172	Results of an AIEOP (Associazione Italiana di Ematologia e Oncologia Pediatrica) Randomized Clinical Trial in Children with Low- and Intermediate-Risk Relapsed Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2014, 124, 65-65.	0.6	0
173	Structural Variations Identified By Whole Transcriptome Sequencing (RNA-Seq) in Childhood ALL with Different Response to Therapy. <i>Blood</i> , 2014, 124, 3768-3768.	0.6	8
174	Detection of PICALM-MLLT10 (CALM-AF10) and outcome in children with T-lineage acute lymphoblastic leukemia. <i>Leukemia</i> , 2013, 27, 2419-2421.	3.3	25
175	Quiescent leukaemic cells account for minimal residual disease in childhood lymphoblastic leukaemia. <i>Leukemia</i> , 2013, 27, 1204-1207.	3.3	45
176	The MLL recombinome of acute leukemias in 2013. <i>Leukemia</i> , 2013, 27, 2165-2176.	3.3	393
177	Linking genomic lesions with minimal residual disease improves prognostic stratification in children with T-cell acute lymphoblastic leukaemia. <i>Leukemia Research</i> , 2013, 37, 928-935.	0.4	16
178	Novel clinical trials for pediatric leukemias: lessons learned from genomic analyses. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 612-619.	0.9	5
179	Single-cell mutational profiling and clonal phylogeny in cancer. <i>Genome Research</i> , 2013, 23, 2115-2125.	2.4	105
180	What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia?. <i>Haematologica</i> , 2013, 98, 1226-1231.	1.7	65

#	ARTICLE	IF	CITATIONS
181	The silent mutational landscape of infant <i>MLL</i> – <i>AF4</i> pro- $\beta$ acute lymphoblastic leukemia. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 954-960.	1.5	50
182	Developmental timing of mutations revealed by whole-genome sequencing of twins with acute lymphoblastic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 7429-7433.	3.3	49
183	PAX5/ETV6 alters the gene expression profile of precursor B cells with opposite dominant effect on endogenous PAX5. <i>Leukemia</i> , 2013, 27, 992-995.	3.3	24
184	Natural history of acute lymphoblastic leukemia in neurofibromatosis type 1 monozygotic twins. <i>Leukemia</i> , 2013, 27, 1778-1781.	3.3	5
185	New MLLT10 gene recombinations in pediatric T-acute lymphoblastic leukemia. <i>Blood</i> , 2013, 121, 5064-5067.	0.6	53
186	Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. <i>Haematologica</i> , 2013, 98, 1702-1710.	1.7	121
187	Impact of IKZF1 deletions on IKZF1 expression and outcome in Philadelphia chromosome negative childhood BCP-ALL. Reply to "Incidence and biological significance of IKZF1/Ikaros gene deletions in pediatric Philadelphia chromosome negative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia". <i>Haematologica</i> , 2013, 98, e164-e165.	1.7	16
188	An Attempt to Induce Transient Immunosuppression Pre-Erythrocytapheresis in a Girl with Sickle Cell Disease, a History of Severe Delayed Hemolytic Transfusion Reactions and Need for Hip Prosthesis. <i>Hematology Reports</i> , 2013, 5, e11.	0.3	7
189	The Polo-Like Kinase 1 (PLK1) Inhibitor NMS-P937 Is Effective in a New Model of Disseminated Primary CD56+ Acute Monoblastic Leukaemia. <i>PLoS ONE</i> , 2013, 8, e58424.	1.1	31
190	CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data. <i>PLoS ONE</i> , 2013, 8, e74825.	1.1	20
191	Philadelphia-Like Signature In Childhood Acute Lymphoblastic Leukemia: The AIEOP Experience. <i>Blood</i> , 2013, 122, 353-353.	0.6	9
192	The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories. <i>Blood</i> , 2013, 122, 743-743.	0.6	6
193	PAX5 Fusion Genes Activate The STAT5 Signaling Pathway Through Lck Over-Expression. <i>Blood</i> , 2013, 122, 3738-3738.	0.6	0
194	Novel Chimeric Transcripts Involving PAX5 in B-Cell Precursor ALL. <i>Blood</i> , 2013, 122, 1367-1367.	0.6	1
195	Multivariate Analysis Reveals a miRNA Profile Correlated To Karyotype and Outcome In Pediatric B-Cell Precursor ALL. <i>Blood</i> , 2013, 122, 2597-2597.	0.6	0
196	Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute lymphoblastic leukemia. <i>Leukemia</i> , 2012, 26, 902-909.	3.3	106
197	Mesenchymal stem cells from Shwachman–Diamond syndrome patients display normal functions and do not contribute to hematological defects. <i>Blood Cancer Journal</i> , 2012, 2, e94-e94.	2.8	17
198	Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia. <i>Haematologica</i> , 2012, 97, 1582-1593.	1.7	95

#	ARTICLE	IF	CITATIONS
199	Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups. <i>British Journal of Haematology</i> , 2012, 158, 772-777.	1.2	39
200	Loss of CBL E3-ubiquitinase activity in B-lineage childhood acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2012, 159, 115-119.	1.2	6
201	Glutathione S-transferase homozygous deletions and relapse in childhood acute lymphoblastic leukemia: a novel study design in a large Italian AIEOP cohort. <i>Pharmacogenomics</i> , 2012, 13, 1905-1916.	0.6	16
202	An Inv(16)(p13.3q24.3)-Encoded CBFA2T3-GLIS2 Fusion Protein Defines an Aggressive Subtype of Pediatric Acute Megakaryoblastic Leukemia. <i>Cancer Cell</i> , 2012, 22, 683-697.	7.7	213
203	Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. <i>Leukemia</i> , 2012, 26, 2245-2253.	3.3	96
204	The Interlaboratory Robustness of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses of Hematological Malignancies Performed by an International Network Involving 26 Laboratories. <i>Blood</i> , 2012, 120, 1399-1399.	0.6	6
205	A Childhood Leukaemia Cluster in Milan: Possible Role of Pandemic AH1N1 Swine Flu Virus.. <i>Blood</i> , 2012, 120, 2496-2496.	0.6	0
206	CI-FISH, GEP, and SNPs Correlate Genomic Categories with Risk Stratification in Children with T-ALL.. <i>Blood</i> , 2012, 120, 2485-2485.	0.6	0
207	CRLF2 Rearrangement Is Not Associated with Activated mTOR Pathway in NOD/SCID/huALL Xenograft Mouse Model.. <i>Blood</i> , 2012, 120, 2518-2518.	0.6	0
208	MLLT10 Gene Promiscuity Unravels Involvement of RNA Processing Genes in Pediatric T-Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 1431-1431.	0.6	0
209	Composite Single Cell Genetics and Clonal Phylogeny in Acute Lymphoblastic Leukaemia. <i>Blood</i> , 2012, 120, 122-122.	0.6	4
210	Fine Tuning of Surface CRLF2 Expression and Its Associated Signalling Profile in Childhood B Cell Precursor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 1409-1409.	0.6	9
211	Role of MRD in Ph+ Pediatric Acute Lymphoblastic Leukemia Patients Treated with and without Tyrosine Kinase Inhibitor in the Esphall Study. <i>Blood</i> , 2012, 120, 1467-1467.	0.6	0
212	Gain-of-function mutations in interleukin-7 receptor- $\alpha$ (IL7R $\alpha$ ) in childhood acute lymphoblastic leukemias. <i>Journal of Experimental Medicine</i> , 2011, 208, 901-908.	4.2	307
213	Minimally manipulated whole human umbilical cord is a rich source of clinical-grade human mesenchymal stromal cells expanded in human platelet lysate. <i>Cytotherapy</i> , 2011, 13, 786-801.	0.3	104
214	Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia. <i>Blood</i> , 2011, 118, 5559-5564.	0.6	83
215	DNA methyltransferase 3a hot-spot locus is not mutated in pediatric patients affected by acute myeloid or T-cell acute lymphoblastic leukemia: an Italian study. <i>Haematologica</i> , 2011, 96, 1886-1887.	1.7	11
216	Genomic Imbalances Are Confined to Non-Proliferating Cells in Paediatric Patients with Acute Myeloid Leukaemia and a Normal or Incomplete Karyotype. <i>PLoS ONE</i> , 2011, 6, e20607.	1.1	4

#	ARTICLE	IF	CITATIONS
217	Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. <i>Blood</i> , 2011, 118, 2077-2084.	0.6	370
218	Defining the correct role of minimal residual disease tests in the management of acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2011, 155, 45-52.	1.2	23
219	Low prevalence of IDH1 gene mutation in childhood AML in Italy. <i>Leukemia</i> , 2011, 25, 173-174.	3.3	9
220	Implementation of array based whole-genome high-resolution technologies confirms the absence of secondary copy-number alterations in MLL-AF4-positive infant ALL patients. <i>Leukemia</i> , 2011, 25, 175-178.	3.3	39
221	Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1391-1401.	1.1	8
222	Clinical outcome and monitoring of minimal residual disease in patients with acute lymphoblastic leukemia expressing the <i>MLL/ENL</i> fusion gene. <i>American Journal of Hematology</i> , 2011, 86, 993-997.	2.0	4
223	T-cell lymphoblastic lymphoma shows differences and similarities with T-cell acute lymphoblastic leukemia by genomic and gene expression analyses. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 1063-1075.	1.5	44
224	Gain-of-function mutations in interleukin-7 receptor- $\beta$ (IL7R) in childhood acute lymphoblastic leukemias. <i>Journal of Experimental Medicine</i> , 2011, 208, 1333-1333.	4.2	6
225	International Standardization of Minimal Residual Disease Assessment for in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) Expressing m-BCR-ABL Transcripts: Updated Results of Quality Control Procedures by the EWALL and ESG-MRD-ALL Consortia. <i>Blood</i> , 2011, 118, 2535-2535.	0.6	4
226	Poor Prognosis for IKZF1 Intra-Gene Deletions in Pediatric Ph <sup>+</sup> B-Cell Precursor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2011, 118, 3518-3518.	0.6	1
227	Acute Lymphoblastic Leukemia in Children with Down Syndrome: A Report From the Ponte Di Legno Study Group. <i>Blood</i> , 2011, 118, 3579-3579.	0.6	8
228	Transcriptome Sequence Analysis of Pediatric Acute Megakaryoblastic Leukemia Identifies An <i>Inv(16)(p13.3;q24.3)</i> -Encoded CBFA2T3-GLIS2 Fusion Protein As a Recurrent Lesion in 39% of Non-Infant Cases: A Report From the St. Jude Children's Research Hospital "Washington University Pediatric Cancer Genome Project. <i>Blood</i> , 2011, 118, 757-757.	0.6	7
229	Acute Lymphoblastic Leukemia Natural History in Neurofibromatosis Type 1 Monozygotic Twins. <i>Blood</i> , 2011, 118, 2414-2414.	0.6	0
230	The Genomic Landscape of TEL-AML1+ ( <i>ETV6-RUNX1</i> ) Acute Lymphoblastic Leukaemia. <i>Blood</i> , 2011, 118, 403-403.	0.6	2
231	Phenotypical and Functional Characterization of Mesenchymal Stem Cells Derived From Patients Affected by Schwachman-Diamond Syndrome. <i>Blood</i> , 2011, 118, 1336-1336.	0.6	0
232	Lack of Protein Kinase C Alpha Is Associated with Poor Prognosis in Pediatric T-Lineage Acute Lymphoblastic Leukemia. <i>Blood</i> , 2011, 118, 744-744.	0.6	0
233	MiR-125b Cooperates with BCR-ABL and Enhances Therapy Resistance in Childhood Ph+ ALL. <i>Blood</i> , 2011, 118, 78-78.	0.6	0
234	Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. <i>Blood</i> , 2010, 115, 1006-1017.	0.6	305

#	ARTICLE	IF	CITATIONS
235	Acquisition of genome-wide copy number alterations in monozygotic twins with acute lymphoblastic leukemia. <i>Blood</i> , 2010, 115, 3553-3558.	0.6	87
236	Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. <i>Blood</i> , 2010, 116, 3013-3022.	0.6	110
237	Identification of immunophenotypic signatures by clustering analysis in pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2010, 85, 138-141.	2.0	8
238	PTPN11 mutations in childhood acute lymphoblastic leukemia occur as a secondary event associated with high hyperdiploidy. <i>Leukemia</i> , 2010, 24, 232-235.	3.3	17
239	DNA copy-number abnormalities do not occur in infant ALL with t(4;11)/MLL-AF4. <i>Leukemia</i> , 2010, 24, 169-176.	3.3	54
240	Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. <i>Blood</i> , 2010, 115, 3206-3214.	0.6	685
241	C20orf94 deletion Is Strongly Associated with TEL/AML1 Rearrangement and Links Illegitimate V(D)J Recombination with Gender Bias In Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2010, 116, 1718-1718.	0.6	1
242	Optimal response to thalidomide in a patient with thalassaemia major resistant to conventional therapy. <i>Blood Transfusion</i> , 2010, 8, 63-5.	0.3	35
243	TEL-AML1 Affects the Regulation of Cytoskeleton and Causes Alteration In Cellular Adhesive and Migratory Properties In An In Vitro Model of Pre-Leukemia.. <i>Blood</i> , 2010, 116, 3624-3624.	0.6	0
244	Dominant-Negative Impact of PAX5/TEL on Downstream Targets of PAX5 and Essential Pre-B Cell Receptor Genes. <i>Blood</i> , 2010, 116, 3231-3231.	0.6	0
245	PAX5/TEL Has An Opposite Dominant Effect on Endogenous PAX5, Affecting Its Transcriptional Regulation, B Cell Adhesion and BCR Signaling In Murine Pre-BI Cells. <i>Blood</i> , 2010, 116, 2482-2482.	0.6	0
246	Biological Features and Prognostic Impact of CRLF2 Overexpression In Childhood ALL. <i>Blood</i> , 2010, 116, 271-271.	0.6	0
247	WT1 Expression at the Diagnosis of Childhood AML Has No Prognostic Value but Corresponds with the Biological Characteristics of Leukemic Cells - Results From European Multicenter Study.. <i>Blood</i> , 2010, 116, 1684-1684.	0.6	0
248	ETV6-RUNX1 fusion gene and additional genetic changes in infant leukemia: a genome-wide analysis. <i>Cancer Genetics and Cytogenetics</i> , 2009, 193, 86-92.	1.0	6
249	Integration of genomic and gene expression data of childhood ALL without known aberrations identifies subgroups with specific genetic hallmarks. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 22-38.	1.5	62
250	Successful Application of OPLS-DA for the Discrimination of Wild-Type and Mutated Cells in Acute Lymphoblastic Leukemia. <i>QSAR and Combinatorial Science</i> , 2009, 28, 822-828.	1.5	9
251	IGH and ICK gene rearrangements as PCR targets for pediatric Burkitt's lymphoma and mature B-ALL MRD analysis. <i>Laboratory Investigation</i> , 2009, 89, 1182-1186.	1.7	23
252	Simultaneous occurrence of acute myeloid leukaemia with mutated nucleophosmin (NPM1) in the same family. <i>Leukemia</i> , 2009, 23, 199-203.	3.3	7

#	ARTICLE	IF	CITATIONS
253	Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. <i>Leukemia</i> , 2009, 23, 1073-1079.	3.3	137
254	Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study. <i>Leukemia</i> , 2009, 23, 1472-1479.	3.3	48
255	The TEL-AML1 leukemia fusion gene dysregulates the TGF- $\beta$ 2 pathway in early B lineage progenitor cells. <i>Journal of Clinical Investigation</i> , 2009, 119, 826-36.	3.9	98
256	DOWN'S Syndrome Acute Lymphoblastic LEUKEMIA: A HIGHLY Heterogeneous DISEASE DRIVEN by an Aberrant CRLF2/JAK2 Cooperation â€“ A REPORT FROM the Ibfm-STUDY GROUP.. <i>Blood</i> , 2009, 114, 11-11.	0.6	2
257	Monozygotic Twins with Childhood ALL Demonstrate Prenatal Origin of the Philadelphia Chromosome and Post-Natal Ikaros Deletion.. <i>Blood</i> , 2009, 114, 87-87.	0.6	0
258	Prevalence and Prognostic Impact of CEBPA mutations in Children with AML Treated with the AIEOP-LAM 2002/01 Protocol.. <i>Blood</i> , 2009, 114, 2643-2643.	0.6	0
259	Genomic and Transcriptomic Analyses Revealed Differences and Similarities Between T-Lbl and T-ALL .. <i>Blood</i> , 2009, 114, 2943-2943.	0.6	0
260	In Infant ALL with t(4;11)/MLL-AF4 Multiple and Phenotypically Distinct CD19+ BM Subsets Initiate Leukemia in NOD/SCID Mice... <i>Blood</i> , 2009, 114, 1432-1432.	0.6	0
261	Acute lymphoblastic leukemia and Down syndrome. <i>Cancer</i> , 2008, 113, 515-521.	2.0	51
262	Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. <i>Leukemia</i> , 2008, 22, 771-782.	3.3	339
263	Genomic analysis of different clonal evolution in a twin pair with t(12;21) positive acute lymphoblastic leukemia sharing the same prenatal clone. <i>Leukemia</i> , 2008, 22, 208-211.	3.3	6
264	Efficient detection of leukemia-related fusion transcripts by multiplex PCR applied on a microelectronic platform. <i>Leukemia</i> , 2008, 22, 294-302.	3.3	9
265	Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. <i>Lancet, The</i> , 2008, 372, 1484-1492.	6.3	318
266	Somatically acquired <i>JAK1</i> mutations in adult acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , 2008, 205, 751-758.	4.2	318
267	PAX5/TEL Acts as a Transcriptional Repressor Causing Down-modulation of CD19, Enhances Migration to CXCL12, and Confers Survival Advantage in pre-B1 Cells. <i>Cancer Research</i> , 2008, 68, 181-189.	0.4	49
268	Time Point-Dependent Concordance of Flow Cytometry and RQ-PCR in the MRD Detection in Childhood ALL: The Experience of the AIEOP-BFM- ALL MRD Study Group. <i>Blood</i> , 2008, 112, 700-700.	0.6	3
269	Short Time Latency in Infant Leukemia with ETV6/RUNX1 fusion Gene. <i>Blood</i> , 2008, 112, 4882-4882.	0.6	0
270	Hepatocyte Growth Factor Receptor c-MET Is Associated with FAS and When Activated Enhances Drug-induced Apoptosis in Pediatric B Acute Lymphoblastic Leukemia with TEL-AML1 Translocation. <i>Journal of Biological Chemistry</i> , 2007, 282, 29384-29393.	1.6	17



#	ARTICLE	IF	CITATIONS
271	Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. <i>Leukemia</i> , 2007, 21, 706-713.	3.3	139
272	Acute lymphoblastic leukemia with t(4;11) in children 1 year and older: The "big sister"™ of the infant disease?. <i>Leukemia</i> , 2007, 21, 642-646.	3.3	21
273	Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. <i>Leukemia</i> , 2007, 21, 604-611.	3.3	626
274	Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements. <i>Leukemia</i> , 2007, 21, 1481-1487.	3.3	29
275	Acute Lymphoblastic Leukemia. , 2007, , 337-347.		1
276	Prognostic Impact of Minimal Residual Disease (MRD) in Children Is Different in B or T Lineage Acute Lymphoblastic Leukemia: Results of Trial AIEOP-BFM ALL 2000.. <i>Blood</i> , 2007, 110, 1425-1425.	0.6	2
277	Collaboration between Activating Mutations in JAK2 and Trisomy 21 in the Acute Lymphoblastic Leukemias of Down Syndrome (DS).. <i>Blood</i> , 2007, 110, LB6-LB6.	0.6	2
278	TEL/ARG induces cytoskeletal abnormalities in 293T cells. <i>Cancer Letters</i> , 2006, 241, 79-86.	3.2	4
279	Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. <i>Blood</i> , 2006, 107, 4514-4523.	0.6	238
280	Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. <i>Leukemia</i> , 2006, 20, 1103-1108.	3.3	278
281	Consensus guidelines for microarray gene expression analyses in leukemia from three European leukemia networks. <i>Leukemia</i> , 2006, 20, 1385-1392.	3.3	47
282	Monitoring of minimal residual disease in leukemia, advantages and pitfalls. <i>Annals of Medicine</i> , 2006, 38, 512-521.	1.5	15
283	The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis. <i>Haematologica</i> , 2006, 91, 322-30.	1.7	21
284	Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. <i>Blood</i> , 2005, 106, 1419-1422.	0.6	152
285	Somatic PTPN11 mutations in childhood acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2005, 129, 333-339.	1.2	78
286	Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection. <i>Leukemia</i> , 2005, 19, 49-56.	3.3	129
287	Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 273-286.	2.0	17
288	Immunogenotype Changes Preval in Relapses of Young Children with TEL-AML1-Positive Acute Lymphoblastic Leukemia and Derive Mainly from Clonal Selection. <i>Clinical Cancer Research</i> , 2005, 11, 7720-7727.	3.2	33

#	ARTICLE	IF	CITATIONS
289	Acute Lymphoblastic Leukaemia Cells Carrying the t(12;21) Translocation Are Highly Sensitive to Alemtuzumab Mediated Cell Lysis.. Blood, 2005, 106, 872-872.	0.6	4
290	Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology. Haematologica, 2005, 90, 382-90.	1.7	72
291	High incidence and unique features of antigen receptor gene rearrangements in TEL-AML1-positive leukemias. Leukemia, 2004, 18, 84-91.	3.3	29
292	Development of a quantitative-PCR method for specific FLT3/ITD monitoring in acute myeloid leukemia. Leukemia, 2004, 18, 1441-1444.	3.3	23
293	Identification of preleukemic precursors of hyperdiploid acute lymphoblastic leukemia in cord blood. Genes Chromosomes and Cancer, 2004, 40, 38-43.	1.5	78
294	Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood, 2004, 104, 307-313.	0.6	265
295	Highly Sensitive Mutations Detection in BCR-ABL Positive Leukemia Prior and during Imatinib Treatment.. Blood, 2004, 104, 1985-1985.	0.6	1
296	PTPN11 and RAS Gene Mutation Pattern Identifies an Unique Feature of Upregulated RAS Function in Infant ALL.. Blood, 2004, 104, 996-996.	0.6	0
297	KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Haematologica, 2004, 89, 920-5.	1.7	126
298	Heterogeneity of the 7q36 breakpoints in the t(7;12) involvingETV6 in infant leukemia. Genes Chromosomes and Cancer, 2003, 38, 191-200.	1.5	30
299	FLT3 internal tandem duplication in childhood acute myeloid leukaemia: association with hyperleucocytosis in acute promyelocytic leukaemia. British Journal of Haematology, 2003, 120, 89-92.	1.2	56
300	Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia, 2003, 17, 1013-1034.	3.3	485
301	Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring. Leukemia, 2003, 17, 1573-1582.	3.3	47
302	Comparison between TaqMan and LightCycler technologies for quantification of minimal residual disease by using immunoglobulin and T-cell receptor genes consensus probes. Leukemia, 2003, 17, 2517-2524.	3.3	24
303	Gene expression profile unravels significant differences between childhood and adult Ph+ acute lymphoblastic leukemia. Leukemia, 2003, 17, 2234-2237.	3.3	16
304	Standardization and quality control studies of "real-time" quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia " A Europe Against Cancer Program. Leukemia, 2003, 17, 2318-2357.	3.3	1,359
305	Rituximab for Immune Hemolytic Anemia following T- and B-Cell-Depleted Hematopoietic Stem Cell Transplantation. Acta Haematologica, 2003, 109, 43-45.	0.7	27
306	Sensitivity to imatinib but low frequency of the TEL/PDGFRbeta fusion protein in chronic myelomonocytic leukemia. Haematologica, 2003, 88, 408-15.	1.7	30

#	ARTICLE	IF	CITATIONS
307	Combined expression of pT1± and Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 3788-3793.	3.3	184
308	Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial. Blood, 2002, 99, 2541-2544.	0.6	110
309	Monitoring minimal residual disease using chromosomal translocations in childhood ALL. Best Practice and Research in Clinical Haematology, 2002, 15, 21-35.	0.7	16
310	Results of minimal residual disease (MRD) evaluation and MRD-based treatment stratification in childhood ALL. Best Practice and Research in Clinical Haematology, 2002, 15, 623-638.	0.7	10
311	Molecular characterization of a new recombination of the SIL/TAL-1 locus in a child with T-cell acute lymphoblastic leukaemia. British Journal of Haematology, 2002, 118, 1011-1018.	1.2	14
312	Prospective molecular monitoring of BCR/ABL transcript in children with Ph+ acute lymphoblastic leukaemia unravels differences in treatment response. British Journal of Haematology, 2002, 119, 445-453.	1.2	34
313	Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet, The, 2001, 358, 1239-1241.	6.3	199
314	Association of gastric and Waldeyer's ring lymphoma: a molecular study. , 2000, 18, 15-19.		10
315	t(7;12)(q36;p13), a new recurrent translocation involving ETV6 in infant leukemia. Genes Chromosomes and Cancer, 2000, 29, 325-332.	1.5	60
316	Quantitative multiparametric immunophenotyping in acute lymphoblastic leukemia: correlation with specific genotype. I. ETV6/AML1 ALLs identification. Leukemia, 2000, 14, 1225-1231.	3.3	84
317	Microclustering of TEL-AML1 translocation breakpoints in childhood acute lymphoblastic leukemia. Genes Chromosomes and Cancer, 2000, 29, 219-228.	1.5	53
318	Fusion of ETV6 to the Caudal-Related Homeobox Gene CDX2 in Acute Myeloid Leukemia With the t(12;13)(p13;q12). Blood, 1999, 93, 1025-1031.	0.6	95
319	The Tyrosine Kinase Abl-Related Gene ARG Is Fused to ETV6 in an AML-M4Eo Patient With a t(1;12)(q25;p13): Molecular Cloning of Both Reciprocal Transcripts. Blood, 1999, 94, 4370-4373.	0.6	103
320	Immunoglobulin Light Chain Kappa Deletion Rearrangement as a Marker of Clonality in Mantle Cell Lymphoma. Leukemia and Lymphoma, 1999, 36, 147-150.	0.6	13
321	Clonal stability in children with acute lymphoblastic leukemia (ALL) who relapsed five or more years after diagnosis. Leukemia, 1999, 13, 190-195.	3.3	38
322	Prenatal origin of acute lymphoblastic leukaemia in children. Lancet, The, 1999, 354, 1499-1503.	6.3	583
323	Fusion of ETV6 to the Caudal-Related Homeobox Gene CDX2 in Acute Myeloid Leukemia With the t(12;13)(p13;q12). Blood, 1999, 93, 1025-1031.	0.6	7
324	The Tyrosine Kinase Abl-Related Gene ARG Is Fused to ETV6 in an AML-M4Eo Patient With a t(1;12)(q25;p13): Molecular Cloning of Both Reciprocal Transcripts. Blood, 1999, 94, 4370-4373.	0.6	7

#	ARTICLE	IF	CITATIONS
325	Autoreactive B cell clones in marginal-zone B cell lymphoma (MALT lymphoma) of the stomach. <i>Leukemia</i> , 1998, 12, 247-249.	3.3	18
326	Identification of new partner chromosomes involved in fusions with the ETV6 (TEL) gene in hematologic malignancies. , 1998, 21, 223-229.		35
327	Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. <i>Lancet</i> , The, 1998, 352, 1731-1738.	6.3	876
328	Molecular Analysis of the Progression from <i>Helicobacter pylori</i> -Associated Chronic Gastritis to Mucosa-Associated Lymphoid-Tissue Lymphoma of the Stomach. <i>New England Journal of Medicine</i> , 1998, 338, 804-810.	13.9	230
329	Identification of Two Novel Isoforms of the ZNF162 Gene: A Growing Family of Signal Transduction and Activator of RNA Proteins. <i>Genomics</i> , 1997, 42, 268-277.	1.3	11
330	Unbalanced t(3;12) in a case of juvenile myelomonocytic leukemia (JMML) results in partial trisomy of 3q as defined by FISH. <i>Leukemia</i> , 1997, 11, 1465-1468.	3.3	13
331	Immunoglobulin heavy chain Diversity genes rearrangement pattern indicates that MALT-type gastric lymphoma B cells have undergone an antigen selection process. <i>British Journal of Haematology</i> , 1997, 97, 830-836.	1.2	41
332	Incidence and Clinical Relevance of TEL/AML1 Fusion Genes in Children With Acute Lymphoblastic Leukemia Enrolled in the German and Italian Multicenter Therapy Trials. <i>Blood</i> , 1997, 90, 571-577.	0.6	268
333	Incidence and Clinical Relevance of TEL/AML1 Fusion Genes in Children With Acute Lymphoblastic Leukemia Enrolled in the German and Italian Multicenter Therapy Trials. <i>Blood</i> , 1997, 90, 571-577.	0.6	11
334	Purification, cDNA Cloning, and Tissue Distribution of Bovine Liver Aldehyde Oxidase. <i>Journal of Biological Chemistry</i> , 1995, 270, 31037-31045.	1.6	96
335	Chromosomal Mapping, Isolation, and Characterization of the Mouse Xanthine Dehydrogenase Gene. <i>Genomics</i> , 1994, 23, 390-402.	1.3	55
336	Prevalence of Anti-Hepatitis C Virus Seroconversion in Polytransfused Thalassemic Patients. <i>Vox Sanguinis</i> , 1991, 60, 188-188.	0.7	4